Can Menopause Cause Depression? Understanding the Hormone-Mood Link
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 13 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
Can menopause cause depression? SWAN data say yes. Who’s at risk, what’s driving the hormone-mood link, and what actually works — therapy, SSRIs/SNRIs, HRT.
The brain is exquisitely sensitive to estrogen and progesterone. It's had these hormones in a particular pattern its whole life, and now that pattern is broken. That's not a character flaw. That's physiology.
If you’re searching whether menopause can cause depression, you’re probably trying to figure out whether what you’re feeling — the heaviness, the loss of interest in things you used to like, the slow draining of energy and motivation — is “just menopause” or something that deserves real treatment. The honest answer is that yes, the menopause transition meaningfully raises the risk of depressive symptoms for many women, and the distinction between “hormonal” and “depression” is less useful than it sounds, because both deserve treatment.
This guide walks through what the longitudinal data actually show about menopause and depression, who’s at highest risk, and what works — from the evidence-based psychotherapies to the medications and hormonal options that have a place when symptoms are severe.
Key takeaways
The menopause transition is a window of increased risk for depressive symptoms, with the perimenopausal stage carrying higher risk than premenopausal years — per SWAN longitudinal data.
Women with a prior history of depression, premenstrual mood disorders, postpartum depression, or significant life stressors are at higher risk for symptoms during the transition.
Effective treatment exists. Psychotherapy — particularly CBT and interpersonal therapy — is well-supported. SSRIs and SNRIs are first-line for moderate-to-severe depression and, at appropriate doses, also reduce vasomotor symptoms.
Hormone therapy is not a primary depression treatment but can help when vasomotor symptoms and sleep disruption are clearly driving mood symptoms. The decision is individualized.
New or worsening depressive symptoms in midlife always warrant clinical evaluation — both to rule out medical contributors and to start effective treatment promptly.
The short answer: yes, menopause can cause or contribute to depression
The most rigorous answer comes from the Study of Women’s Health Across the Nation (SWAN). Bromberger and colleagues’ 10-year longitudinal analysis found elevated risk of high depressive symptoms during the perimenopausal transition compared to premenopausal years, with risk easing somewhat in postmenopause for many women.
That’s a meaningful finding. It says the transition itself is a risk window, not just a backdrop against which depression happens to occur. The mechanisms — hormonal effects on serotonin and HPA-axis function, sleep loss from night sweats, life stress, and reactivation of prior depression — are well-characterized, and they translate into clear treatment implications.
Why menopause increases the risk of depression
Several inputs converge during the transition:
Women are gaslit into believing that their bodies are problematic and that consequently they themselves are problematic. We are forced to make do with a medical system largely designed around the needs of men, and we have our medical concerns dismissed as 'not that bad' or fabricated.
Hormonal effects on mood circuitry. Estrogen modulates serotonin synthesis, receptor sensitivity, and several other neurotransmitter systems involved in mood regulation. Fluctuating and declining estrogen disrupts these systems. The same neurochemistry underlies why some women experience mood symptoms with normal monthly hormonal shifts (PMS, PMDD), and why pregnancy and the postpartum period — also marked by dramatic hormonal change — are higher-risk windows for depression.
Sleep disruption. Vasomotor symptoms fragment sleep, and chronic sleep loss independently raises depression risk. The loop is bidirectional: depression worsens sleep, bad sleep worsens depression. The fuller picture is in our guides on menopause night sweats and menopause insomnia.
Life stressors. Caregiving for aging parents, parenting through adolescence, career intensification, relationship transitions, and bereavement often cluster in the 40s and 50s. None of these cause depression by themselves, but they raise the load.
Reactivation of prior depression. Women with a history of depression, PMDD, or postpartum depression are at higher risk for symptoms during the menopause transition. This is one of the most clinically actionable details — it changes the conversation about when to act.
When depression is most likely
SWAN data identify perimenopause — and particularly late perimenopause, when cycles are highly irregular but periods haven’t fully stopped — as the highest-risk window. Symptoms often ease somewhat after estrogen stabilizes in postmenopause, though this isn’t universal and the prior-history subgroup carries persistent risk.
For more on staging the transition, our pillar guide on the stages of menopause walks through STRAW+10.
What menopause depression can look like
The presentation can be subtle. A few patterns are common enough to be worth naming:
Slow loss of interest in activities, relationships, and projects that used to engage you
Persistent low mood or numbness that doesn’t lift with the usual things that used to lift it
Fatigue out of proportion to your actual schedule — covered in our guide on menopause fatigue
Sleep disturbance that may or may not include night sweats
Cognitive complaints — slowed thinking, word-finding difficulty — that overlap with what gets called brain fog
Withdrawal from social and work obligations
There's an interesting perception that women's health is not real medicine — like, say, studying cancer or strokes — that periods and menopause are not as worthy of medical attention or research funding. Even in terms of insurance coverage, women's health has always been some of the poorest.
Irritability sometimes more prominent than sadness — this is real and well-documented in midlife depression
Hopelessness about the future or about whether anything will help
The overlap with other menopause symptoms — fatigue, sleep loss, cognitive complaints, anxiety — is part of why menopause depression is often under-recognized. The symptoms get attributed to “menopause” without being treated.
If you are experiencing thoughts of self-harm, suicidal thoughts, or feel unable to keep yourself safe, please reach out to professional support — emergency services or a mental health professional — immediately.
What helps: psychotherapy
The strongest non-drug evidence for depression is for cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). Both have established evidence in adults generally and growing evidence for midlife women specifically. The MENOS trials — Mann and colleagues, Lancet Oncology 2012 — adapted CBT for menopausal symptoms with durable effect, including on mood dimensions.
CBT is structured, time-limited (typically 8 to 16 sessions for depression), and increasingly accessible through both in-person therapists and validated digital programs. For mild-to-moderate depression, it’s a reasonable first move. For more severe symptoms, it pairs well with medication.
CBT-I (the insomnia variant) deserves separate mention. Sleep is so consistently a driver of depressive symptoms in this age group that treating sleep often improves mood substantially. Covered in menopause insomnia.
What helps: lifestyle approaches with evidence
Several non-drug strategies have measurable effects on depressive symptoms:
Regular aerobic and strength exercise. Exercise has consistent antidepressant effects in trial data. Three to four sessions per week of moderate-intensity activity, plus some strength training, produces measurable benefit.
Sleep prioritization and structure. Treating sleep often translates directly into improved mood.
Reducing alcohol. Alcohol worsens both depression and sleep architecture independently. For many women, even modest reductions help.
Social engagement and structure. Withdrawal is one of the most reliable amplifiers of depressive symptoms; gentle re-engagement with relationships and routine is one of the most reliable counters.
Mindfulness-based programs. Modest but durable evidence in midlife women.
These approaches won’t carry severe depression on their own. They reduce the load and amplify whatever else you’re doing.
What helps: medication
For moderate-to-severe depression — or for milder depression that isn’t responding to psychotherapy and lifestyle approaches — medication has a clear role.
SSRIs and SNRIs are first-line for depression in adults and have the added advantage, at the right doses, of reducing vasomotor symptoms. The MsFLASH trials, including Joffe and colleagues on venlafaxine in JAMA Internal Medicine in 2014, demonstrated meaningful VMS reduction with low-dose SNRI therapy. For women whose depression and hot flashes both warrant treatment, a single medication can sometimes address both.
The class differences and clinical-context preferences are covered in our medication for hot flashes guide. Briefly: low-dose escitalopram is often preferred when anxiety is prominent; venlafaxine is preferred when VMS reduction is the priority or when paroxetine’s CYP2D6 interaction is a concern (relevant for women on tamoxifen, covered in tamoxifen side effects).
Hormone therapy is not a primary depression treatment. The Menopause Society’s 2022 Hormone Therapy Position Statement is explicit on this: hormone therapy is not indicated for treatment of depressive disorders.
That said, for women whose mood symptoms are clearly driven by severe vasomotor symptoms and sleep loss, treating those underlying drivers with hormone therapy often improves mood meaningfully. There is also some evidence that hormone therapy may have direct mood benefits for women experiencing perimenopausal depression — particularly in the perimenopausal window itself, less so in postmenopause. The decision is individualized and best made with a clinician who knows your history. The broader picture is in our HRT benefits guide.
What’s not depression — and worth ruling out
Several conditions can mimic or amplify depressive symptoms:
Thyroid disease. Hypothyroidism in particular can produce a picture indistinguishable from depression — fatigue, low mood, cognitive slowing, weight gain.
Anemia and other medical contributors. Iron deficiency and vitamin B12 deficiency can produce fatigue and mood symptoms.
Sleep apnea. Cumulative sleep loss produces a picture that overlaps with depression.
Medication side effects. Some prescription medications — including some blood pressure medications, some hormonal contraceptives, and others — can contribute to depressive symptoms.
Substance use. Alcohol, in particular, can drive depressive symptoms.
This isn’t an exhaustive list. The point is that a clinician taking a thorough history and ordering reasonable tests is the right person to sort it out, not a search engine.
What this means for you
Three points worth taking forward:
The menopause transition is a real depression risk window. This isn’t a stigma to absorb — it’s a clinical fact with clear treatment implications.
Prior history matters. If you’ve had depression, PMDD, or postpartum depression, the perimenopausal transition deserves proactive attention. Tell your clinician early.
Treatment works. The evidence for psychotherapy, lifestyle approaches, and antidepressant medication in midlife women is solid. There’s no “first try everything else for a year” requirement when symptoms are interfering with daily life.
When to talk to your doctor
Reasonable triggers — and several urgent ones — for a conversation:
Low mood, loss of interest, or persistent fatigue lasting more than two weeks
Sleep disruption that’s compounding the picture
A history of depression, PMDD, postpartum depression, or anxiety, with symptoms re-emerging
Symptoms interfering with work, relationships, or daily function
Coexisting vasomotor symptoms severe enough to warrant their own treatment
Use of alcohol, sleep aids, or other substances increasing as a way to cope
Urgent: any thoughts of self-harm, suicide, or feeling unable to keep yourself safe. Please contact emergency services or a mental health professional immediately. This is not the kind of symptom to wait on.
If you’d like to prepare for the conversation, our guide on talking to your doctor about menopause walks through what to bring and what to ask.
Frequently asked questions
Can menopause cause depression?
The menopause transition meaningfully raises the risk of depressive symptoms, particularly in perimenopause. SWAN longitudinal data document this elevated risk compared to premenopausal years, with the perimenopausal window — especially late perimenopause — the highest-risk stage.
Who is most at risk for menopause depression?
Women with a prior history of depression, premenstrual dysphoric disorder (PMDD), postpartum depression, or significant life stressors during the transition carry the highest risk. Severe vasomotor symptoms and sleep disruption also raise risk.
Can hormone therapy treat depression?
Hormone therapy is not a primary treatment for depressive disorders, per the Menopause Society’s 2022 statement. It can improve mood for women whose symptoms are clearly driven by severe vasomotor symptoms and sleep loss, and there is some evidence of direct mood benefit in perimenopausal depression. The decision is individualized.
What’s the best medication for menopause depression?
SSRIs and SNRIs are first-line for moderate-to-severe depression and have the additional benefit of reducing hot flashes at appropriate doses. The right choice depends on coexisting conditions, current medications, and history. A clinician’s input is essential.
Will menopause depression go away on its own?
For some women, symptoms ease as estrogen stabilizes in postmenopause. For others, symptoms persist and benefit from active treatment. “Wait it out” is not a sufficient plan when depressive symptoms are affecting daily function — effective treatments exist.
How is menopause depression different from regular depression?
The underlying biology and treatment approach are similar. The distinction is mostly about timing — depression that emerges during the perimenopausal transition has hormonal contributors that may not be present at other life stages, and treating coexisting vasomotor symptoms and sleep disruption is often part of the plan. The diagnostic threshold and the importance of treatment are the same.
Sources
Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women’s Health Across the Nation (SWAN) over 10 years. Obstetrics and Gynecology Clinics of North America. 2011;38(3):609-625.
Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Internal Medicine. 2014;174(7):1058-1066. (MsFLASH.)
Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncology. 2012;13(3):309-318.
Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstetrics and Gynecology Clinics of North America. 2011;38(3):567-586.
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015;175(4):531-539.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Prescription medications referenced — including SSRIs, SNRIs, and hormone therapy — require evaluation by a clinician, have specific contraindications, and may interact with other medications. Do not start, stop, or change a prescription medication without speaking to your clinician. If you are experiencing severe symptoms, thoughts of self-harm, or feel unable to keep yourself safe, please contact emergency services or a mental health professional immediately.
